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The dopamine (DA) transporter (DAT) facilitates high-affinity pre-
synaptic DA reuptake that temporally and spatially constrains DA
neurotransmission. Aberrant DAT function is implicated in attention-
deficit/hyperactivity disorder and autism spectrum disorder. DAT is a
major psychostimulant target, and psychostimulant reward strictly
requires binding to DAT. DAT function is acutely modulated by
dynamic membrane trafficking at the presynaptic terminal and a PKC-
sensitive negative endocytic mechanism, or “endocytic brake,” con-
trols DAT plasma membrane stability. However, the molecular basis
for the DAT endocytic brake is unknown, and it is unknown whether
this braking mechanism is unique to DAT or common to monoamine
transporters. Here, we report that the cdc42-activated, nonreceptor
tyrosine kinase, Ack1, is a DAT endocytic brake that stabilizes DAT at
the plasma membrane and is released in response to PKC activation.
Pharmacologic and shRNA-mediated Ack1 silencing enhanced basal
DAT internalization and blocked PKC-stimulated DAT internalization,
but had no effects on SERT endocytosis. Both cdc42 activation and
PKC stimulation converge on Ack1 to control Ack1 activity and DAT
endocytic capacity, and Ack1 inactivation is required for stimulated
DAT internalization downstream of PKC activation. Moreover, consti-
tutive Ack1 activation is sufficient to rescue the gain-of-function
endocytic phenotype exhibited by the ADHD DAT coding variant,
R615C. These findings reveal a unique endocytic control switch
that is highly specific for DAT. Moreover, the ability to rescue the
DAT(R615C) coding variant suggests that manipulating DAT traf-
ficking mechanisms may be a potential therapeutic approach to
correct DAT coding variants that exhibit trafficking dysregulation.
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Dopamine (DA) is a modulatory neurotransmitter critical forlocomotion and reward (1), and dopaminergic (DAergic) dys-
regulation is linked to multiple neuropsychiatric disorders, includ-
ing Parkinson’s disease, schizophrenia, attention-deficit/hyperactivity
disorder (ADHD), and autism spectrum disorder (ASD) (2, 3).
Presynaptic recapture, facilitated by the high-affinity DA transporter
(DAT), spatially and temporally restricts extracellular DA avail-
ability (4–6). Addictive psychostimulants that target DAT and its
monoamine transporter homologs for 5HT (SERT) and NE (NET)
are either competitive ligands, such as cocaine, or competitive sub-
strates, such as amphetamine (7). Although these drugs interact with
DAT, SERT, and NET with equimolar affinity, their binding to
DAT is requisite for reward (8, 9). Transporter inhibitors with dif-
ferential DAT, SERT, and NET specificity are widely used to treat
neuropsychiatric disorders (10, 11). However, their therapeutic ef-
ficacy differs significantly among patients, consistent with the model
that monoamines may differentially contribute to the pathogenesis
of these disorders (10, 12). Thus, regulatory mechanisms specific
to DAT, SERT, or NET may provide a novel route to develop
transporter-specific therapeutics.
DAT plasma membrane expression is requisite for efficacious
extracellular DA removal and to replenish presynaptic DA stores
(13). Indeed, DAT allelic and coding variants have been identified
in a variety of neuropsychiatric disorders, including ADHD, ASD,
infantile Parkinsonism, and bipolar disorder (14–20), underscoring
that even subtle DAT functional changes exert impactful conse-
quences on DAergic neurotransmission. DAT is acutely regu-
lated by membrane trafficking, and either protein kinase C (PKC)
activation or AMPH exposure rapidly deplete DAT surface
expression (5, 7, 21, 22). Intriguingly, a DAT coding variant,
R615C, identified in an ADHD proband, exhibits profound mem-
brane instability due to highly accelerated basal endocytosis (16),
suggesting that dysregulated DAT membrane trafficking may con-
tribute to the etiology of DA-related disorders.
Studies from our laboratory (23) and others (24) indicate that a
unique negative regulatory mechanism, or “endocytic brake,” sta-
bilizes DAT surface expression. PKC activation releases the endo-
cytic brake, accelerates DAT internalization, and thereby reduces
DAT surface levels and function. The cellular basis of this negative
regulatory mechanism are completely undefined. Moreover, it is
unknown whether the endocytic brake exists in DAergic terminals
and whether it is specific to DAT.
Activated by cdc42 kinase 1 (Ack1) is a nonreceptor tyrosine
kinase that is a major cdc42 effector activated via EGF, PDGF,
and m3 muscarinic receptor stimulation (25, 26). Ack1 binds di-
rectly to clathrin heavy chain (27, 28) and is enriched in presyn-
aptic terminals (29). Importantly, Ack1 is inactivated by PKC (26),
and a recent study demonstrated that Ack1 overexpression sup-
presses endocytosis (30). Given these attributes, we asked whether
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Ack1 activity is the penultimate step that engages the DAT
endocytic brake.
Results
Ack1 Negatively Regulates DAT, but Not SERT Endocytosis. Ack1 and
its active, autophosphorylated form, pY284-Ack1 (pAck1) (25,
31), were readily detected in both the DAergic cell line SK-N-
MC and mouse striatum (Fig. S1 A and B). PKC activation sig-
nificantly decreased pAck1 in both SK-N-MC cells (46.5 ± 3.0%
control levels; Fig. S1A) and mouse striatum (78.3 ± 5.2%
control levels; Fig. S1B). Likewise, the highly specific Ack1 in-
hibitor AIM-100 (32) dose-dependently decreased pAck1 in SK-
N-MC cells (Fig. S1C) and dramatically decreased mouse striatal
pAck1 to 13.2 ± 2.2% control levels (Fig. S1D). Thus, Ack1 is
expressed in DAergic cell lines and striatum, and either PKC
activation or AIM-100 inactivates Ack1 in both these model
systems.
We predicted that if Ack1 imposes the DAT endocytic brake,
then Ack1 inactivation would release the brake and decrease both
DAT function and surface expression. Indeed, AIM-100 signifi-
cantly decreased [3H]DA uptake in SK-N-MC cells (IC50 = 50.2 ±
9.9 μM) and striatal slices (Fig. 1 A and B) and significantly re-
duced DAT surface levels to 72.5 ± 6.4% control levels in mouse
striatum (Fig. 1C). DAT surface loss in response to AIM-100 was
due to a significant increase in the DAT internalization rate, to
192.9 ± 28.6% control levels (Fig. 1D), demonstrating that Ack1
negatively regulates DAT endocytosis. AIM-100 effects were
specific to DAT and had no effect on the SERT endocytic rate
measured in SERT-SK-N-MC cells (Fig. 1D; P = 0.89). In-
terestingly, high AIM-100 concentrations (>20 μM) inhibited DAT
function to a much larger degree than what could be attributed to
membrane trafficking. DAT loss of function was not due to trans-
membrane Na+ gradient disruption, as AIM-100 had no effect on
Na+-dependent alanine uptake (Fig. S2A). To our surprise, AIM-
100 also dose-dependently inhibited SERT function (Fig. S2B),
despite exerting no effect on SERT trafficking (Fig. 1D). We noted
that AIM-100 bears DAT and SERT pharmacophore properties
similar to piperazine derivatives, such as GBR12909 (Fig. S2C). We
therefore hypothesized that, in addition to its known function as
a high-affinity Ack1 inhibitor, AIM-100 may also be a low-affinity,
competitive DAT and SERT inhibitor. Whole cell binding studies
revealed that AIM-100 competitively inhibited DAT and SERT
binding to [3H]WIN 35428 and [3H]imipramine, respectively (Fig.
S2D), supporting the premise that AIM-100 is a DAT and SERT
inhibitor. However, GBR12909 had no effect on pAck1 levels (Fig.
S2E), indicating that DAT ligand binding does not globally in-
activate Ack1. Moreover, a 10-fold lower AIM-100 concentration
that efficaciously decreased p284-Ack1 levels (2 μM; Fig. S1C),
also significantly increased DAT internalization rates (Fig. S2F).
Thus, distinct endocytic mechanisms regulate DAT and SERT,
and Ack1 activity is required to impose the DAT endocytic brake.
Moreover, AIM-100 is, coincidentally, a low-affinity, competitive
DAT and SERT inhibitor.
Constitutive and Regulated DAT Endocytosis Are Differentially
Dependent on Clathrin. Ack1 is recruited to clathrin-coated pits
via clathrin heavy chain interactions (27, 28). Thus, we hypothe-
sized that clathrin is required to release the Ack1-imposed brake.
To test clathrin-dependence, we acutely inhibited clathrin with
pitstop2 and measured DAT internalization ±AIM-100 and
±PMA. Pitstop2 pretreatment significantly attenuated both AIM-
100– and PKC-stimulated DAT internalization, but had no effect
on basal DAT endocytosis (Fig. 2 A and B), suggesting that
stimulated DAT endocytosis is clathrin-dependent, whereas con-
stitutive DAT endocytosis is clathrin-independent. We further
used total internal resonance fluorescence microscopy (TIRFM)
to examine clathrin and surface DAT under basal conditions,
compared with transferrin receptor (TfR), a protein known to
undergo robust clathrin-mediated endocytosis. Alexa 594-Tf
colocalized markedly with eGFP-clathrin across the plasma
membrane, and distinct Tf/clathrin puncta moved away from the
TIRF field during imaging, consistent with clathrin-mediated en-
docytosis (Fig. 2C). In contrast, TagRFP-T-DAT was diffusely
distributed across the plasma membrane and was enriched in
cellular microspikes, with little apparent clathrin colocalization
(Fig. 2C). Taken together with the pitstop2 data, these data sup-
port that constitutive DAT endocytosis is clathrin-independent,
whereas stimulated DAT endocytosis requires clathrin.
Cdc42 Negatively Regulates DAT, but Not SERT, Endocytosis. Ack1 is
a major cdc42 effector, suggesting that cdc42 may contribute to the
DAT endocytic brake, upstream of Ack1. To test this possibility, we
measured DAT surface levels in DAT SK-N-MC cells and striatal
DAergic terminals following acute treatment with two structurally
distinct cdc42 inhibitors, casin and pirl1. Both casin and pirl1 sig-
nificantly reduced DAT surface levels in SK-N-MC cells (Fig. 3 A
and B), and casin significantly decreased surface DAT in mouse
striatum (Fig. 3C). DAT surface loss in response to cdc42 in-
hibition was due to profound DAT endocytic acceleration (238.0 ±
15.5% control levels, Fig. 3D). In contrast, pirl1 did not signifi-
cantly affect SERT internalization (Fig. S3A). We further tested
whether PKC and cdc42 impact DAT surface stability in
independent or convergent manners. Pretreatment ±casin
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Fig. 1. Ack1 activity stabilizes DAT at the plasma membrane. (A) [3H]DA
uptake. DAT SK-N-MC cells were treated with the indicated AIM-100 con-
centrations for 30 min at 37 °C, and [3H]DA uptake was measured as de-
scribed in SI Methods. Data are expressed as percent specific DA uptake ±
SEM (n = 12). (B) Ex vivo slice uptake. Striatal slices were treated ±20 μM
AIM-100, 60 min, 37 °C and [3H]DA uptake was assessed as described in SI
Methods. *P < 0.05, Student’s t test, n = 6 hemislices obtained from two
independent mice. (C) Ex vivo slice biotinylation. Striatal slices were treated
±20 μM AIM-100 for 30 min at 37 °C, and surface proteins were isolated by
biotinylation as described in SI Methods. (C, Upper) Representative immu-
noblots. (C, Lower) Average DAT surface levels expressed as percent vehicle-
treated levels ± SEM. **P < 0.01, Student’s t test, n = 3. (D) Internalization
assays. DAT and SERT internalization rates were measured in SK-N-MC cells
±20 μM AIM-100 as described in SI Methods. (D, Upper) Representative im-
munoblots showing the total DAT and SERT surface pools at t = 0 (T), strip
control (S), and internalized protein during either vehicle (V) or AIM-100 (A)
treatments. (D, Lower) Average internalization rates expressed as percent
vehicle-treated ± SEM. *P < 0.02, Student’s t test; n = 5 (DAT); n = 3 (SERT).
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(Fig. 3A) or ±pirl1 (Fig. 3B) significantly attenuated PKC-stim-
ulated DAT endocytosis. Moreover, pirl1 and PMA coapplica-
tion had no additive effect on DAT internalization (Fig. 3D).
Taken together, these results demonstrate that cdc42 activity is
required to impose the DAT endocytic brake, likely via the same
pathway as PKC and potentially upstream of Ack1. Moreover,
these results further support that distinct endocytic mechanisms
govern DAT and SERT surface stability.
Ack1 Inactivation Is Required to Release the DAT Endocytic Brake,
Downstream of PKC or cdc42. We next used two efficacious
hAck1-targeted shRNAs, 10 and 12 (Fig. S4A), to test whether
Ack1 is required to (i) engage the DAT endocytic brake and (ii)
stimulate DAT endocytosis by PKC activation or cdc42 inhibition.
The most efficacious hAck1 shRNA, 10, significantly increased
basal DAT endocytosis to 138.7 ± 12.3% control levels (Fig. 4B),
consistent with Ack1’s requisite role as the DAT endocytic brake.
Moreover, Ack1 depletion with either shRNA 10 or 12 significantly
attenuated stimulated DAT endocytosis, either via PKC stimula-
tion (Fig. 4C) or cdc42 inhibition (Fig. 4D). In sum, these results
support that Ack1 is required to engage the DAT endocytic brake.
Although perturbing Ack1 enhanced DAT endocytosis, we next
asked whether there is a direct causal link between Ack1 in-
activation and either cdc42 inhibition or PKC activation to release
the DAT endocytic brake. To test this, we coexpressed DAT with
either wild-type, constitutively active (S445P), or kinase dead
(K158A) Ack1 isoforms (33) (see Fig. S4B for Ack1 mutant
overexpression profiles). We predicted that if Ack1 inactivation
were required to release the DAT endocytic brake, then S445P-
Ack1 would block accelerated DAT internalization in response to
either PKC activation or cdc42 inhibition. Wild-type Ack1 over-
expression had no effect on basal or accelerated DAT endocytosis
in response to PKC activation or cdc42 inhibition (Fig. 5 B–D). In
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Fig. 2. Stimulated DAT endocytosis is clathrin-dependent, whereas constitu-
tive DAT endocytosis is clathrin-independent. (A and B) DAT internalization
assay. DAT SK-N-MC cells were pretreated ±25 μM pitstop2 for 10 min at 37 °C
and rapidly chilled, and DAT internalization rates were measured as described
in SI Methods ±20 μM AIM-100 (A) or ±1 μM PMA (B). (A and B, Upper) Rep-
resentative immunoblots showing total surface DAT at t = 0 (T), strip control
(S), and internalized DAT during vehicle (V), AIM-100 (A), or PMA (P) treat-
ments. (A and B, Lower) Average DAT internalization rates expressed as per-
cent vehicle-treated ± SEM. Asterisks indicate a significant difference from
vehicle. *P < 0.03; ***P < 0.005, one-way ANOVA with Bonferroni’s multiple
comparison test; n = 7 (A); n = 4–6 (B). (C) TIRF microscopy. Time-lapse TIRF
images were captured as described in SI Methods. (C, Upper) SK-N-MC cells
stably expressing eGFP-clathrin labeled with Tf-Alexa594. White arrows in-
dicate Tf/clathrin colocalized puncta that move away from the TIRF field
during image capture. (C, Lower) SK-N-MC cells stably cotransfected with
TagRFP-T-DAT and eGFP-clathrin.
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Fig. 3. Cdc42 stabilizes DAT surface expression. (A and B) Cell surface bio-
tinylation. DAT SK-N-MC cells were pretreated ±10 μM casin (A) or ±20 μM
pirl1 (B) for 30 min at 37 °C, followed by treatment ±1 μM PMA for 30 min at
37 °C. Relative DAT surface levels were measured by biotinylation as de-
scribed in SI Methods. Representative immunoblots are shown at the top of
each panel. (A) Casin treatment. Average DAT surface levels expressed as
percent vehicle levels ± SEM. Asterisks indicate a significant difference from
vehicle control. *P < 0.05; **P < 0.01, one-way ANOVA with Bonferroni’s
multiple comparison test; n = 5–6. (B) Pirl1 treatment. Average DAT surface
levels expressed as percent vehicle levels ± SEM. Asterisks indicate a signif-
icant difference from vehicle control. *P < 0.02; **P < 0.01, one-way ANOVA
with Bonferroni’s multiple comparison test; n = 3. (C) Ex vivo striatal slice
biotinylation. Mouse striatal slices were treated ±10 μM casin for 30 min at
37 °C, and relative DAT surface levels were measured by biotinylation as
described in SI Methods. (C, Upper) Representative immunoblot. (C, Lower)
Average DAT surface levels expressed as percent vehicle-treated ± SEM. *P <
0.05, Student’s t test; n = 10. (D) Internalization assay. DAT internalization
rates were measured ±1 μM PMA, ±20 μM pirl1, or with PMA/pirl1 coap-
plication for 10 min at 37 °C, as described in SI Methods. (D, Upper) Repre-
sentative immunoblots showing total surface DAT at t = 0 (T), strip control
(S), and internalized DAT during vehicle (V), PMA (P), or pirl1 (PR) treat-
ments. (D, Lower) Average DAT internalization rates expressed as percent
vehicle rate ± SEM. Asterisks indicate a significant difference from vehicle
control. **P < 0.01; ***P < 0.005, one-way ANOVA with Bonferroni’s mul-
tiple comparison test; n = 9–13.
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contrast, S445P-Ack1 significantly attenuated both PKC-stimulated
(Fig. 5C) and pirl1-stimulated (Fig. 5D) DAT internalization.
K158A-Ack1 had no significant effect either basal (P = 0.30) or
pirl1-stimulated (P = 0.30) DAT internalization (Fig. 5 B and D),
but significantly inhibited PKC-stimulated DAT endocytosis
(100.1 ± 5.2% control level, Fig. 5C). Although the K158A mutant
lacks kinase activity (34), it was unknown, a priori, whether this
mutant would exert a dominant negative effect. Ack1 activation is
required for targeting to clathrin-coated pits (30). Thus, it is not
surprising the kinase deadmutant failed to exert a dominant effect on
DAT internalization. Taken together, these results provide a causal
link between upstream PKC or cdc42 stimuli and Ack1 inactivation
as requisite steps in releasing the DAT endocytic brake.
Ack1 Activity Restores Normal Trafficking to a DAT Coding Variant
Expressed in an ADHD Proband. A recent study reported that a DAT
coding variant, R615C, identified in an ADHD proband, lacks
endocytic braking, resulting in enhanced basal endocytosis and in-
ability to undergo PKC- and AMPH-stimulated endocytosis (16). We
asked whether constitutive Ack1 activation could restore the endo-
cytic brake and thereby rescue the DAT(R615C) gain-of-function
endocytic phenotype. DAT(R615C) expressed in SK-N-MC cells in-
ternalized significantly faster than wild-type DAT (Fig. 5 E and F) and
was defective in PKC-stimulated endocytosis (Fig. S3B), consistent
with the previous report (16). Remarkably, S445P-Ack1 significantly
decreased DAT(R615C) basal endocytosis to wild-type DAT levels
(Fig. 5D), but did not restore PKC-stimulated endocytosis (Fig. S3B).
Discussion
Reuptake inhibitors are used to treat a variety of neuropsychiatric
disorders, including depression, obsessive-compulsive disorder,
and ADHD (10, 35). These agents are differential selective for
SERT, NET, and DAT, and their clinical efficacy varies consid-
erably across the population (10, 12). Transporter-specific cellular
regulation has the potential to lead to novel and selective thera-
peutic approaches that manipulate transporters intrinsically, rather
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Fig. 4. shRNA-mediated Ack1 depletion increases basal DAT internalization
and abolishes stimulated DAT endocytosis in response to PKC activation or
cdc42 inhibition. (A–D) DAT internalization assays: DAT SK-N-MC cells were
transduced with lentiviral particles expressing either pGIPZ vector (vec), non-
silencing (NS), hAck1 10 (10), or hAck1 12 (12) shRNAs, and DAT internalization
rates were measured ±1 μM PMA (C) or ±20 μM pirl1 (D) as described in SI
Methods. (A) Representative immunoblots for each transduction condition
showing total surface DAT at t = 0 (T), strip control (S), and internalized DAT
during vehicle (V), PMA (P) or pirl1 (PR) treatments. (B) Basal DAT in-
ternalization rates expressed as percent vector-transduced rates ± SEM. *P <
0.04, Student’s t test; n = 6. (C) PKC-stimulated DAT internalization rates
expressed as percent vehicle rate ± SEM for each transduction condition. As-
terisks indicate a significant difference from vector-transduced control. *P <
0.03; **P < 0.01, one-way ANOVA with Dunnett’s multiple comparison test;
n = 4–7. (D) Pirl1-induced DAT internalization rates expressed as percent ve-
hicle rate ± SEM for each transduction condition. Asterisks indicate a signifi-
cant difference from vector-transduced control, *P < 0.02; **P < 0.01, one-way
ANOVA with Dunnett’s multiple comparison test; n = 4–7.
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Fig. 5. Ack1 inactivation is required for stimulated DAT endocytosis, and
constitutive Ack1 activation rescues ADHD DAT coding variant R615C
endocytic dysfunction. Internalization assays: SK-N-MC cells were cotrans-
fected with the indicated DAT and Ack1 isoforms and DAT internalization
rates were measured during treatment ±1 μM PMA or 20 μM pirl1 as de-
scribed in SI Methods. (A–D) Wild-type DAT cotransfected with the indicated
Ack1 cDNAs. (A) Representative immunoblots showing total surface DAT at
t = 0 (T), strip control (S), and internalized DAT during vehicle (V), 1 μM PMA
(P), or 20 μM pirl1 (PR) treatments. (B) Average basal DAT internalization
rate expressed as percent vector cotransfected rate ± SEM, one-way ANOVA;
P = 0.10; n = 8–9. (C) Average PKC-stimulated DAT internalization rate
expressed as percent vector cotransfected rate ± SEM. **P < 0.01 compared
with vector control, one-way ANOVA with Dunnett’s multiple comparison
test; n = 8–9. (D) Average pirl1-stimulated DAT internalization rates
expressed as percent vector cotransfected rate ± SEM. *P < 0.02 compared
with vector control, one-way ANOVA with Dunnett’s multiple comparison
test; n = 8–9. (E and F) DAT vs. DAT(R615) internalization rates ±S445P-Ack1.
(E) Representative immunoblots. (F) Average DAT internalization rates
expressed as percent wild-type DAT control rate ± SEM. **P < 0.01 compared
with indicated sample, one-way ANOVA with Bonferroni’s multiple com-
parison test; n = 8–11.
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than extrinsically. In the current study, we identified an endocytic
regulatory mechanism that is selective for DAT, but not SERT. We
previously reported that PKC-stimulated DAT internalization is
also selectively dependent upon binding to the neuronal GTPase,
Rin, whereas neither SERT nor the GABA transporter binds Rin
(36). Taken together with our current findings, these data are
consistent with a model wherein distinct mechanisms differentially
regulate DAT and SERT surface stability.
There are conflicting reports regarding whether constitutive
and regulated DAT internalization are clathrin-dependent. Gene
silencing studies suggest that both constitutive and PKC-stimu-
lated DAT internalization in nonneuronal cell lines is clathrin-
dependent (37); however, whether chronic clathrin depletion
artifactually skews these studies is uncertain. A recent study
examining DAT trafficking in a knock-in mouse encoding a DAT
extracellular epitope tag observed only modest DAT endocytosis
and little/no clathrin colocalization under basal conditions (38).
However, it is unclear whether antibody-bound DAT traffics
similar to native DAT, as we investigate here. Multiple studies
also demonstrate that DAT partitions into cholesterol-rich
membrane microdomains (36, 39–44) and that the membrane
raft protein flotillin-1 is required for PKC- and AMPH-mediated
DAT internalization (42), consistent with a clathrin-independent
endocytic mechanism. However, a separate study reported that
flotillin-1 contributes to DAT membrane mobility rather than
PKC-stimulated DAT internalization (45). Our findings suggest
that basal DAT internalization is clathrin-independent, whereas
stimulated DAT internalization is clathrin-dependent. Consis-
tent with these data, we previously reported that basal and PKC-
stimulated DAT internalization are mediated by independent
mechanisms (46, 47) and that constitutive and PKC-stimulated
DAT internalization are dynamin-independent and -dependent,
respectively (40).
Cdc42 directly activates Ack1, and cdc42 inhibition released the
DAT endocytic brake in a manner that required Ack1 inactivation
(Fig. 5). Several forms of clathrin-independent endocytosis require
cdc42 (48–50). In contrast, we found that cdc42 negatively regu-
lates DAT endocytosis via Ack1 activation (Fig. 3), and that
stimulated DAT endocytosis in response to Ack1 inactivation is
clathrin-dependent (Fig. 2). Thus, it appears that cdc42 impacts
DAT internalization in a unique fashion, in contrast to its more
commonly known function in promoting endocytosis.
Given our current findings, and in light of previous reports, we
propose the following model of basal and PKC-regulated DAT
endocytosis (Fig. 6). Under basal conditions, an Ack1-mediated
endocytic brake stabilizes DAT at the plasma membrane, and cdc42
promotes the braking mechanism via Ack1 activation. Basal in-
ternalization that occurs while the endocytic brake is engaged is
clathrin- and dynamin-independent. PKC activation decreases Ack1
activity, which releases the endocytic brake and accelerates DAT
internalization via a clathrin- and dynamin-dependent mechanism,
resulting in intracellular DAT sequestration.
What are the molecular players orchestrating the Ack1-imposed
DAT endocytic brake and PKC-mediated Ack1 inactivation? PIP2
depletion inactivates Ack1 (30), and both DAT (51) and SERT
(52) bind to PIP2. However, DAT mutants lacking PIP2 binding
exhibited plasma membrane instability in HEK cells, whereas
disrupting SERT/PIP2 interactions did not affect SERT mem-
brane trafficking. These findings raise the possibility that PIP2
effects on Ack1 activity may specifically influence DAT surface
stability. PKC activation also increases DAT ubiquitination via a
Nedd4-2–mediated mechanism that is required for enhanced
DAT endocytosis (53). Nedd4-2 also interacts with Ack1 and is
recruited to clathrin-rich vesicles (54), and Nedd4-2/Ack1 in-
teractions drive Ack1 degradation in an Ack1 activity-dependent
fashion. Thus, it is possible that Nedd4-2 serves as a dual func-
tion player in the DAT endocytic brake by controlling Ack1
protein turnover as well as DAT ubiquitination.
Multiple DAT coding variants and missense mutants have been
reported in ADHD, ASD, and infantile Parkinsonism patients,
implicating DAT dysfunction as a common risk factor for several
DA-related disorders (15–17, 19). Many DAT coding variants
exhibit basal anomalous DA efflux and loss of AMPH-induced
DA efflux. However, the ADHD-associated DAT(R615C) variant
lacks plasma membrane stability due to rapid basal endocytosis
and is unable to sequester in response to PKC activation or
AMPH exposure. We were able to capitalize on the Ack1-medi-
ated DAT endocytic brake to restore wild-type surface stability
to DAT(R615C) (Fig. 5D). Not unexpectedly, S445P-Ack1 also
prevented DAT(R615C) from responding to PKC stimulation
(Fig. S3B), similar to its effect on wild-type DAT (Fig. 5B).
Nevertheless, our ability to rescue DAT(R615C) endocytic dys-
function raises the tantalizing possibility that genetically target-
ing DAT trafficking may hold promise for DAT coding variants
with inherent membrane trafficking dysregulation.
Materials and Methods
All of the methods used in this study have been previously reported by our
laboratory. All animal studies were conducted according to University of
Massachusetts Medical School Institutional Animal Care and Use Committee-
approved protocol A-1506. Transporter function was determined by radio-
tracer flux assays (23, 46, 55), and relative initial DAT internalization rates
were measured by using reversible biotinylation (23, 36, 40, 47, 56). DAT
surface expression changes in cell lines (23, 40, 46, 47, 55, 56) and mouse
striatal slices (40, 57) were measured by using surface biotinylation. Finally,
DAT surface dynamics were assessed by using TIRFM (40). For detailed ex-
perimental protocols, refer to SI Methods.
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